SLATE-ASSET-MANAGEMENT
15.9.2022 20:01:38 CEST | Business Wire | Press release
Slate Asset Management (“Slate”), a global alternative investment platform targeting real assets, today announced a strategic partnership with Roswall Development Inc. (“Roswall”), a fully integrated Canadian renewable energy company based in Halifax, Nova Scotia, through the acquisition of a significant minority stake in the company.
Roswall is an experienced developer of renewable energy projects offering complete energy solutions for infrastructure, industries, and communities in partnership with private and public enterprises. Roswall’s full suite of services includes consulting, strategic planning, design-build installations, development, financing, and operations of renewables projects. The leadership team at Roswall has been active in the renewable energy industry for over 15 years, having successfully developed, constructed, and operated C$150 million of wind, solar, and retrofit projects across North America. Roswall was also awarded the first independent retail electricity licence in Nova Scotia in October 2021.
The partnership with Slate will help fund future renewables projects developed by Roswall, which has a significant and actionable pipeline of wind development opportunities that will support its retail operation by providing 100% clean electricity to its customers. Additionally, it has a growing turnkey business focused on commercial, institutional, and industrial markets. The Roswall team will also benefit from the global expertise, resources, and relationships of the broader Slate platform as it looks to scale its platform across Canada and North America.
“We believe that proven and scalable renewable energy solutions can meaningfully improve the resiliency of our cities and communities by reducing energy consumption, minimizing the environmental impacts of energy production, and increasing the reliability and efficiency of our energy sources,” said Christian Schmid, Managing Director and Global Head of Infrastructure at Slate. “Roswall’s experienced team has been on the front lines of the significant energy transition taking place globally over the past decade, working to broaden access to affordable, reliable, sustainable, and modern energy sources across North America. We look forward to partnering closely with the Roswall team on integrations across our own real estate portfolio and supporting their mission of continuing to accelerate the energy transition worldwide.”
Daniel Roscoe, Chief Executive Officer at Roswall, said: “The energy economy is changing at a dramatic pace. We have shown with our work in Nova Scotia and the Caribbean that locally produced renewable energy combined with energy retrofits can provide cost savings, emission reductions, and energy security. We are excited to find a likeminded partner in Slate, with the capacity and experience to grow our approach and accelerate energy transition and climate action here in Nova Scotia and abroad.”
Slate is an active investor in sustainable assets and technologies that advance the global energy transition and enable cities and communities to reach their carbon emission reduction goals. The firm recently hired Jeff Rodgers as Managing Director, North American Infrastructure to support the continued growth of Slate’s infrastructure platform globally, with a focus on uncovering investment opportunities tied to the global energy transition in the US and Canada.
About Slate Asset Management
Slate Asset Management is a global alternative investment platform targeting real assets. We focus on fundamentals with the objective of creating long-term value for our investors and partners. Slate’s platform has a range of real estate and infrastructure investment strategies, including opportunistic, value add, core plus and debt investments. We are supported by exceptional people and flexible capital, which enable us to originate and execute on a wide range of compelling investment opportunities. Visit slateam.com to learn more.
About Roswall Development Inc.
Roswall Development Inc. is an experienced developer of renewable energy projects, encompassing all aspects from financing and construction to operation. We are focused on enabling regions, industries, and public institutions to become energy self-sufficient through development of renewable energy systems and energy efficiency retrofits. Roswall's team has over 15 years of experience with over $150M of wind, solar and retrofit projects successfully developed, constructed and operated. Active in both Canada and the Caribbean, Roswall is helping accelerate the energy transition by helping companies and institutions get to zero emissions cost effectively. Learn more at roswall.ca.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220915005149/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom